You are here: Industry Insights > Avastin

News List

American Academy of Ophthalmology Applauds UnitedHealthcare for Clarifying Drug Policy on Ophthalmic Avastin Alternatives firstwordpharma
August 18, 2021
The Academy commends UnitedHealthcare (UHC) for acting quickly to clarify its policy regarding the use of two biosimilars untested for ophthalmic/intravitreal use as alternatives to the sight-saving drug Avastin. UHC removed the drugs, Mvasi and Zirabev.
Financial Report: Roche 1H Results contractpharma
July 23, 2021
Diagnostics Division sales grew 49% due to high demand for COVID-19 tests and strong momentum in routine testing.
NICE approves Lynparza plus Avastin via Cancer Drugs Fund pharmatimes
March 19, 2021
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca/MSD’s Lynparza combined with Roche’s Avastin for certain patients with ovarian cancer via the Cancer Drugs Fund (CDF).
Roche’s Tecentriq/Avastin combo improves survival in liver cancer pharmatimes
January 14, 2021
Roche is planning to present updated data confirming that its immunotherapy combination, consisting of Tecentriq (atezolizumab) and Avastin (bevacizumab), improves overall survival (OS) in patients with a type of liver cancer.
USFDA defers action on BLA for Avastin biosimilar, notifies Biocon Biologics, Mylan expresspharma
December 28, 2020
To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the standard review process.
Roche obtains EC approval for Tecentriq/Avastin to treat liver cancer pharmaceutical-technology
November 05, 2020
Roche has obtained approval from the European Commission for Tecentriq (atezolizumab) and Avastin (bevacizumab) combination to treat adult patients with advanced or unresectable hepatocellular carcinoma (HCC).
Roche gets positive CHMP opinion for Tecentriq plus Avastin to treat liver cancer expresspharma
September 21, 2020
The recommendation from the CHMP is based on results from the Phase III IMbrave150 study, which showed that Tecentriq in combination with Avastin reduced the risk of disease worsening or death.
Roche's Tecentriq/Avastin combo wins US approval pharmatimes
June 04, 2020
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen cleared to treat unresectable or metastatic liver cancer.
Genentech gets FDA approval for Tecentriq, Avastin combo for HCC pharmaceutical-business-review
June 03, 2020
Genentech has secured approval from the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).
FDA Accepts BLA for Proposed Biosimilar Bevacizumab for Review americanpharmaceuticalreview
March 10, 2020
Mylan and Biocon announced the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA) for MYL-1402O, a proposed biosimilar to Avastin® (bevacizumab), for review under the 351(k) pathway.

Previous page 1 2 3 Next page